Wayne Gulliver1, Charles Lynde2, Jan P Dutz2, Ronald B Vender2, Jensen Yeung2, Marc Bourcier2, Pierre-Luc Dion2, Chi-Ho Hong2, Gordon Searles2, Yves Poulin2. 1. Faculty of Medicine, Division of Dermatology, Memorial University, St. John's NLDepartment of Medicine, Division of Dermatology, University of Toronto, Toronto, ON and Lynderm Research Inc., Markham, ONDepartment of Dermatology and Skin Science, Child and Family Research Institute, University of British Columbia, Vancouver, BCDepartment of Medicine, McMaster University, Hamilton ON, Service of Dermatology, St. Joseph's Hospital, Hamilton, ON and Dermatrials Research, Dermatology Centre, Hamilton, ONDivision of Dermatology, Department of Medicine, University of Toronto, Toronto, ONFaculty of Medicine, Sherbrooke University, Sherbrooke, QCDepartment of Medicine, Division of Dermatology, Laval University, Quebec, QCDepartment of Dermatology and Skin Science, University of British Columbia, Vancouver, BCDepartment of Medicine, Division of Dermatology, University of Alberta, Edmonton, AB and Searles Dermatology & Aesthetics, Edmonton, ABCHUQ, Hotel-Dieu Hospital, Laval University, Quebec, QC wgulliver@newlabresearch.com. 2. Faculty of Medicine, Division of Dermatology, Memorial University, St. John's NLDepartment of Medicine, Division of Dermatology, University of Toronto, Toronto, ON and Lynderm Research Inc., Markham, ONDepartment of Dermatology and Skin Science, Child and Family Research Institute, University of British Columbia, Vancouver, BCDepartment of Medicine, McMaster University, Hamilton ON, Service of Dermatology, St. Joseph's Hospital, Hamilton, ON and Dermatrials Research, Dermatology Centre, Hamilton, ONDivision of Dermatology, Department of Medicine, University of Toronto, Toronto, ONFaculty of Medicine, Sherbrooke University, Sherbrooke, QCDepartment of Medicine, Division of Dermatology, Laval University, Quebec, QCDepartment of Dermatology and Skin Science, University of British Columbia, Vancouver, BCDepartment of Medicine, Division of Dermatology, University of Alberta, Edmonton, AB and Searles Dermatology & Aesthetics, Edmonton, ABCHUQ, Hotel-Dieu Hospital, Laval University, Quebec, QC.
Abstract
OBJECTIVE: Explore the feasibility of Treat to Target in the area of psoriasis as seen in other therapeutic areas such as hypertension, hyperlipidemia, diabetes and rheumatoid arthritis. METHODS: Review validated, measurable targets for psoriasis, including physician global assessment (PGA), psoriasis area and severity index (PASI) and dermatology life quality index (DLQI). Examine principles brought forth in the published European consensus on psoriasis and develop a Canadian consensus on Treat to Target in psoriasis. RESULTS: As PASI and DLQI are not routinely used in the community setting, we are recommending target at a PGA of zero (clear). CONCLUSION: Recommend that the target is a PGA of zero (clear) as it provides a simple and measurable result that the patient and physician can clearly understand.
OBJECTIVE: Explore the feasibility of Treat to Target in the area of psoriasis as seen in other therapeutic areas such as hypertension, hyperlipidemia, diabetes and rheumatoid arthritis. METHODS: Review validated, measurable targets for psoriasis, including physician global assessment (PGA), psoriasis area and severity index (PASI) and dermatology life quality index (DLQI). Examine principles brought forth in the published European consensus on psoriasis and develop a Canadian consensus on Treat to Target in psoriasis. RESULTS: As PASI and DLQI are not routinely used in the community setting, we are recommending target at a PGA of zero (clear). CONCLUSION: Recommend that the target is a PGA of zero (clear) as it provides a simple and measurable result that the patient and physician can clearly understand.
Authors: Marjolein De Bruin-Weller; Tilo Biedermann; Robert Bissonnette; Mette Deleuran; Peter Foley; Giampiero Girolomoni; Jana Hercogová; Chih-Ho Hong; Norito Katoh; Andrew E Pink; Marie-Aleth Richard; Stephen Shumack; Juan F Silvestre; Stephan Weidinger Journal: Acta Derm Venereol Date: 2021-02-17 Impact factor: 3.875
Authors: L Grine; M de la Brassinne; P-D Ghislain; T Hillary; J Lambert; S Segaert; F Willaert; J Lambert Journal: J Eur Acad Dermatol Venereol Date: 2020-01-02 Impact factor: 6.166
Authors: Paolo Gisondi; Marina Talamonti; Andrea Chiricozzi; Stefano Piaserico; Paolo Amerio; Anna Balato; Federico Bardazzi; Piergiacomo Calzavara Pinton; Anna Campanati; Angelo Cattaneo; Paolo Dapavo; Clara De Simone; Valentina Dini; Maria C Fargnoli; Maria L Flori; Marco Galluzzo; Claudio Guarneri; Claudia Lasagni; Francesco Loconsole; Ada Lo Schiavo; Piergiorgio Malagoli; Giovanna Malara; Santo R Mercuri; Maria L Musumeci; Luigi Naldi; Manuela Papini; Aurora Parodi; Concetta Potenza; Francesca Prignano; Franco Rongioletti; Luca Stingeni; Rossana Tiberio; Marina Venturini; Luca Bianchi; Antonio Costanzo; Francesco Cusano; Giampiero Girolomoni; Anna M Offidani; Ketty Peris Journal: Dermatol Ther (Heidelb) Date: 2021-01-11
Authors: Hermenio Lima; Melinda Gooderham; Jan Dutz; Charles Lynde; Hugo Chapdelaine; Anne Ellis; Martin Gilbert; Vincent Ho; Kim Papp; Yves Poulin; Gordon Sussman Journal: Allergy Asthma Clin Immunol Date: 2017-08-24 Impact factor: 3.406